Dentons US LLP
Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
Provided herein are methods for ameliorating an adverse effect of systemic administration of a PEG hyaluronan degrading enzyme to a subject. The methods involve systemically administering a PEGylated hyaluronan degrading enzyme, particularly a PEGylated hyaluronidase, such as any of the animal or bacterial hyaluronidases, to the subject and administering an amount of a corticosteroid sufficient to ameliorate the adverse effect. Also provided are method of treating a hyaluronan-associated disease or condition for single-agent therapy or combination therapy.
Halozyme, Inc.
A A A A A A A A A A A A A A A A A C A A A A A A A A A A
A61P A61P A61P A61P A61P A61K A61K A61P A61K A61P A61K A61P A61K A61P A61P A61P A61P C12Y A61P A61K A61P A61P A61P A61P A61K A61P A61P A61P
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional additional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional
Gregory I. Harold Michael Curtis Xiaoming
Frost Shepard Thompson Li